Last reviewed · How we verify
NCT03780101: PIKA
Pathology and Imaging in Kidney Allografts
trial testing Multi-parametric renal MRI in Renal Transplant Rejection in 29 participants. Terminated before completion.
24 May 2022
Quick facts
| Lead sponsor | NHS Greater Glasgow and Clyde |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 15 February 2019 |
| Primary completion | 24 May 2022 |
| Estimated completion | 24 May 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Multi-parametric renal MRI
Conditions studied
- Renal Transplant Rejection — all drugs for Renal Transplant Rejection →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Fibrosis — all drugs for Fibrosis →
Sponsor
NHS Greater Glasgow and Clyde — full company profile →
Who can join
18 and older, any sex, with Renal Transplant Rejection or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will perform multi-parametric renal MRI in 70 patients with a renal transplant who are undergoing a clinically indicated biopsy of their transplant. The aim of this study is to compare findings on renal MRI with those seen on histology.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Druggability of lipid metabolism modulation against renal fibrosis.
Chen YY, Chen XG, Zhang S. · · 2022 · cited 43× · PMID 33990764 · DOI 10.1038/s41401-021-00660-1 -
Let-7i-5p Regulation of Cell Morphology and Migration Through Distinct Signaling Pathways in Normal and Pathogenic Urethral Fibroblasts.
Zhang K, Yang R, Chen J, Qi E, et al · · 2020 · cited 11× · PMID 32478052 · DOI 10.3389/fbioe.2020.00428
Verify or expand the search:
- PubMed search for NCT03780101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Transplant Rejection
Currently open trials in the same condition.
- NCT03991780 — Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection · Phase 1, PHASE2 · active not recruiting
- NCT03719339 — VIRTUUS Children's Study · active not recruiting
Other NHS Greater Glasgow and Clyde trials
Trials by the same sponsor.
- NCT07403890 — Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis · NA · not yet recruiting
- NCT07372508 — Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions · NA · not yet recruiting
- NCT07391280 — Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department · NA · not yet recruiting
- NCT07048184 — Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing · Phase 2 · not yet recruiting
- NCT06786936 — Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03780101 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NHS Greater Glasgow and Clyde
- Last refreshed: 3 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing